Teleflex Aktie

Teleflex ROE

ROE (Return on Equity) for Teleflex (TFX) pr. 30. mar. 2026 er 0,02. I foregående år var ROE (Return on Equity) 0,08 — en ændring på -79,7 % (lavere).

ROE

0,02

YoY

-79,7%

Senest opdateret:

I 2026 var egenkapitalrentabiliteten (ROE) for Teleflex 0,02, en stigning på -79,7% sammenlignet med 0,08 ROE i det foregående år.
Access this data via the Eulerpool API

Teleflex Aktieanalyse

Hvad laver Teleflex? Teleflex Inc. is a global company founded in 1943. The company is headquartered in Wayne, Pennsylvania, USA and operates in over 40 countries worldwide. It is a leading provider of medical devices, instruments, and accessories for various applications in clinical practice and patient care. The business model of Teleflex is based on the manufacturing and marketing of medical devices and instruments, particularly in the areas of anesthesia, vascular access, interventional medicine, pulmonary and thoracic surgery, urological care, cardiovascular diagnostics, and surgery. The company works closely with medical professionals and clinicians to develop high-quality products that meet the needs of patients and doctors. Teleflex is divided into several business segments, including angiography/diagnostics, anesthesia, oncology, vascular intervention, pulmonology, surgery, and urology. Each of these segments offers a wide range of products and solutions specifically tailored to the needs of doctors and patients. In the angiography/diagnostics segment, Teleflex offers a variety of products that can be used for the diagnosis and treatment of cardiovascular diseases and other medical conditions. These include catheters, guide wires, and sheaths. The anesthesia segment of Teleflex includes products such as ventilation bags, endotracheal tubes, and nebulizer systems. These products are essential for the successful performance of anesthesia procedures and can help doctors save valuable time and resources. The oncology segment of Teleflex offers a wide range of products specifically designed for the treatment of cancer patients. These include catheter-based systems that can facilitate the administration of drugs and other therapies. With the vascular intervention segment, Teleflex offers a comprehensive range of products and solutions specifically designed for the treatment of vascular diseases. These include balloon catheters, stents, and sheaths. The pulmonology segment of Teleflex offers products aimed at facilitating breathing and improving the quality of life for patients with chronic respiratory diseases. These include oxygen concentrators, tracheal tubes, and ventilators. The surgical segment of Teleflex offers a variety of solutions for performing surgical procedures, including surgical instruments, sutures, and wound care materials. The urology segment of Teleflex offers a wide range of products specifically designed for use in urology. These include catheters, wires, and stents. Teleflex is a leading company in the medical technology industry that specializes in the development and marketing of products that improve patients' quality of life and facilitate the work of doctors. With its innovative solutions and a focus on providing the best possible customer service and patient safety, Teleflex has taken on a significant role in the industry and will continue to be an important provider in this market in the future. Teleflex er et af de mest populære virksomheder på Eulerpool.com.

ROE i detaljen

Afkodning af egenkapitalforrentningen (ROE) for Teleflex

Egenkapitalforrentningen (ROE) for Teleflex er en grundlæggende finansiel nøgletal, der vurderer selskabets rentabilitet i forhold til egenkapitalen. ROE, som beregnes ved at dividere nettoindtjeningen med aktionærernes egenkapital, illustrerer, hvor effektivt selskabet genererer overskud på aktionærernes investeringer. En højere ROE indikerer øget effektivitet og profitabilitet.

År-til-år Sammenligning

Analyse af Teleflex's ROE på årsbasis hjælper med at følge rentabilitetstrends og den finansielle performance. En stigende ROE indikerer en forbedret rentabilitet og værdiskabelse for aktionærerne, mens en faldende ROE kan tyde på problemer med at generere overskud eller med håndteringen af egenkapitalen.

Effekter på Investeringer

ROE for Teleflex er afgørende for investorer, der vurderer selskabets rentabilitet, effektivitet og investeringsattraktivitet. En robust ROE angiver selskabets evne til at omdanne egenkapitalinvesteringer til overskud og øger dermed dens tiltrækningskraft for potentielle og nuværende investorer.

Fortolkning af ROE-udsving

Ændringer i Teleflex's ROE kan skyldes svingninger i nettoindtjeningen, egenkapitalen eller begge dele. Disse svingninger bliver undersøgt for at vurdere ledelseseffektiviteten, de finansielle strategier samt de forbundne risici og muligheder, og hjælpe investorer med at træffe velinformerede beslutninger.

Hyppigt stillede spørgsmål om Teleflex aktie

ROE (Return on Equity) af Teleflex var 0,08 0,02

Access this data via the Eulerpool API

Rentabilitet — Teleflex

Alle nøgletal — Teleflex